Nasdaq
$0.9310▼ 3.95%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $12.8MShares out 13.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 9.9Pre-market26.09.09 21:008-KKey event#●●●#●●●#●●●
Cocrystal Pharma, Inc.Bullish
Cocrystal Pharma has completed dosing the last subject in its Phase 1b clinical trial for CDI-988, an oral antiviral candidate for norovirus. No serious adverse events have been reported to date, and preliminary efficacy results are expected to be released in late 2026 or early 2027.…more
$0.9310-3.95%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.21After-hours26.08.22 05:103Ownership
Cocrystal Pharma, Inc.
Carol L. Brosgart, an officer of Cocrystal Pharma, granted a power of attorney to James Martin and Michael D. Harris on August 20, 2026. This authorization empowers the designated attorneys-in-fact to prepare and file required SEC reports, including Forms 3, 4, 5, and Form 144, on her behalf in compliance with Section 16 of the Exchange Act.…more
$0.9310-3.95%vs prev closeView filingShare - 8.18After-hours26.08.19 05:308-KKey event
Cocrystal Pharma, Inc.
Cocrystal Pharma appointed Carol L. Brosgart as a member of its Board of Directors, effective August 12, 2026. There are no arrangements, understandings, or related party transactions involving Ms. Brosgart that require disclosure.…more
$0.9310-3.95%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.9Pre-market26.09.09 20:10#●●●#●●●#●●●
Cocrystal Pharma Completes Dosing in Phase 1b Norovirus Study
Cocrystal Pharma has completed dosing for its Phase 1b clinical trial of the norovirus candidate CDI-988 with no serious adverse events reported so far. Preliminary efficacy results are expected to be released between late 2026 and early 2027.…more
$0.9310-3.95%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.17Regular26.08.18 00:17
●●●●●●●● ●●●●● ●●●●●●
Antiviral therapy expert Dr. Carol Brosgart has joined the Board of Directors at Cocrystal Pharma. This appointment is expected to bolster the clinical development of the company's antiviral pipeline, including its norovirus treatment.…more
$0.9310-3.95%vs prev close - 8.3Pre-market26.08.03 20:00
●●●●●●●● ●●●●● ●●●●●●
코크리스탈 파마가 기존 투자자인 OPKO 헬스로부터 500만 달러 규모의 자금을 조달하며 노로바이러스 치료제 개발에 속도를 냅니다. 이번 유상증자는 연말 노로바이러스 임상 1b상 결과 발표를 앞두고 주요 투자자의 신뢰를 재확인한 것으로 평가됩니다.…more
$0.9310-3.95%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report